(Q42111332)

16 October 2017

0 references

Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used (English)

1 reference

16 October 2017

1 reference

1 reference

2

1 reference

16 October 2017

Jotam G Pasipanodya

1

1 reference

PMC publication ID

2897291

16 October 2017

language of work or name

English

0 references

publication date

3 May 2010

1 reference

16 October 2017

8

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

16 October 2017

54

1 reference

16 October 2017

7

1 reference

16 October 2017

2847-2854

1 reference

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

THE CEPHALIN-CHOLESTEROL FLOCCULATION TEST AS AN AID IN THE DIAGNOSIS OF HEPATIC DISORDERS.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Measuring inconsistency in meta-analyses

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Once-daily dosing in dogs optimizes daptomycin safety

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Role of individual drugs in the chemotherapy of tuberculosis

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Review article: drug-induced hepatotoxicity

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Hypersensitivity hepatitis due to pyrazinamide

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Drug-induced allergic hepatitis

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Mean body weight, height, and body mass index, United States 1960-2002.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

Streptomycin plus pyrazinamide in the treatment of patients excreting isonazid-resistant tubercle bacilli, following previous chemotherapy.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis: Results at 5 Years

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2897291

The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid

30 September 2018

1 reference

12 December 2020

Experience with pyrazinamide

1 reference

12 December 2020

A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association

1 reference

12 December 2020

Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study

1 reference

12 December 2020

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients

1 reference

12 December 2020

Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong

1 reference

12 December 2020

Pyrazinamide-isoniazid: comparison with isoniazid-para-aminosalicylic acid in active pulmonary tuberculosis with the choice of regimens determined by chance

1 reference

12 December 2020

Pyrazinamide-isoniazid in tuberculosis

1 reference

12 December 2020

Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study

1 reference

12 December 2020

Observations on pyrazinamide (Aldinamide) in pulmonary tuberculosis

1 reference

12 December 2020

Absorption, metabolism and excretion of pyrazinamide in man

1 reference

12 December 2020

Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis

1 reference

12 December 2020

A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore

1 reference

12 December 2020

A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre

1 reference

12 December 2020

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council

1 reference

12 December 2020

Treatment of pulmonary tuberculosis with isoniazid and pyrazinamide: experience in 114 cases

1 reference

12 December 2020

Pyrazinamide-isoniazid in low dosage in treatment of pulmonary tuberculosis

1 reference

12 December 2020

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report

1 reference

12 December 2020

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis

1 reference

12 December 2020

A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.01567-09

1 reference

16 October 2017

1 reference

PMC publication ID

2897291

16 October 2017

PubMed publication ID

20439617

1 reference

PMC publication ID

2897291